Research & Development
-
Joe Raedle via Getty Images
Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll
While researchers gain ground understanding long COVID’s impact, viable treatments could still be a long way off.
By Meagan Parrish • June 14, 2024 -
Dr_Microbe via Getty Images
Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.
By Michael Gibney • June 13, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Stock via Getty Images
Despite adcomm rejection, Lykos CEO sees future for MDMA drug
Although the rebuff makes approval “a bit more challenging,” Lykos is moving forward with the psychedelic-based treatment for PTSD.
By Alexandra Pecci • June 12, 2024 -
Stock via Getty Images
Behind the powerful computations, AI’s role in pharma is still beset by challenges
Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.
By Amy Baxter • June 12, 2024 -
Christopher Furlong via Getty Images
As Big Pharma places bigger bets on ADCs, here’s where the field is headed next
With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.
By Michael Gibney • June 11, 2024 -
Sarah Silbiger via Getty Images
FDA’s platform designation aims to ease R&D pain points
A new program creates approval pathways for multiple drugs developed on the same platform.
By Amy Baxter • June 11, 2024 -
Stock via Getty Images
Pharma’s R&D gamble: picking pipeline winners in a risky field
How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.
By Meagan Parrish • June 7, 2024 -
Permission granted by FibroBiologics
Biotech SpotlightRegenerative cell therapy biotech uses IPO to blast into human trials
Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.
By Amy Baxter • June 5, 2024 -
Justin Sullivan via Getty Images
After two Big Pharma deals, Nimbus looks to keep the hits coming
With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.
By Kelly Bilodeau • June 3, 2024 -
Courtesy of Merck & Co.
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.
By Michael Gibney • June 3, 2024 -
Stock via Getty Images
Biotech SpotlightMythic Therapeutics aims to overcome one of ADC’s long-standing challenges
By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.
By Alexandra Pecci • May 30, 2024 -
Stock via Getty Images
As weight loss booms, drugmakers look for an edge with oral options
Supply of GLP-1 medications falls well short of demand, and oral versions of the drugs loom over Eli Lilly and Novo Nordisk’s dominance.
By Amy Baxter • May 28, 2024 -
Stock via Getty Images
Where competition is heating up in pharma
The stage is set for potential blockbuster-level showdowns targeting these three indications.
By Meagan Parrish • May 24, 2024 -
Stock via Getty Images
3 up-and-coming US biotech hotspots
These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.
By Alexandra Pecci • May 21, 2024 -
Stock via Getty Images
After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era
Heather Dean discusses the company’s neuroscience pipeline in epilepsy and narcolepsy and moving from a mass market to a rare disease mentality.
By Alexandra Pecci • May 21, 2024 -
Leon Neal / Getty Images via Getty Images
Why AlphaFold 3 is stirring up so much buzz in pharma
The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.
By Kelly Bilodeau • May 20, 2024 -
Sean Gallup via Getty Images
Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies
Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said.
By Amy Baxter • May 20, 2024 -
Stock via Getty Images
Why H5N1 has scientists and regulators on edge
While the H5N1 threat to humans is still low, the recent influenza outbreak in cattle is presenting strange and challenging hurdles for containment.
By Meagan Parrish • May 17, 2024 -
iStock via Getty Images
Investors put $400M into biotech licensing obesity drugs from China
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
By Gwendolyn Wu • May 16, 2024 -
Stock via Getty Images
5 trends impacting drug spend in the U.S.
Key factors changing how much Americans spend on prescriptions.
By Kelly Bilodeau • May 13, 2024 -
sanjeri via Getty Images
Sponsored by SmartLabsThinking inside the box: How SmartLabs is transforming laboratories for modern science and accelerating innovation
SmartLabs offers the first integrated platform combining re-configurable lab infrastructure, operations and scientific expertise.
May 13, 2024 -
Permission granted by Daiichi Sankyo
Q&AThe Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
The CEO of Daiichi Sankyo’s American business explains why it could be poised to become a “top 10” cancer company.
By Meagan Parrish • May 10, 2024 -
Jemal Countess via Getty Images
OpinionThe judicial microscope on abortion meds puts FDA and industry in a precarious spot
The recent SCOTUS case involving mifepristone exposes the risk of drug safety determinations by judicial fiat.
By Meg Alexander • May 9, 2024 -
jetcityimage via Getty Images
Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown
The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.
By Michael Gibney • May 9, 2024 -
Permission granted by AstraZeneca
Q&AAZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
By Michael Gibney • May 8, 2024
